Drug biotransformation by the cytochrome P-450 enzyme system

Infections in Medicine

Volumn 13, Issue 6, 1996, Pages

  Meyer, Joette M ^a   Rodvold, Keith A ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Cytochrome P 450; Pharmacology

Indexed keywords

ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CARDIOVASCULAR AGENT; CIMETIDINE; CLOMIPRAMINE; CORTICOSTEROID; CYTOCHROME P450; DAPSONE; DEBRISOQUINE; DIAZEPAM; DILTIAZEM; ENALAPRIL; GASTROINTESTINAL AGENT; ISONIAZID; ITRACONAZOLE; KETOCONAZOLE; NIFEDIPINE; NORFLOXACIN; OMEPRAZOLE; PARACETAMOL; PHENYTOIN; PSYCHOTROPIC AGENT; QUINIDINE; SERTRALINE; THEOPHYLLINE; UNINDEXED DRUG; VERAPAMIL; WARFARIN;

ARTICLE; BIOTRANSFORMATION; DRUG METABOLISM; ENZYME INDUCTION; ENZYME INHIBITION; GENETIC POLYMORPHISM; HUMAN;

EID: 0029680201     PISSN: 07496524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Benet LZ, Kroetz DL, Sheiner LB: Biotransformation of drugs, in Hardman JG, Limbird LL, Molinoff PB, et al (eds): Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, McGraw-Hill, 1996, pp 3-28.
2. Renton KW: Factors affecting drug biotransformation. Clin Biochem 19:72-75, 1986.
3. Spatzenegger M, Jaeger W: Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metab Rev 27:397-417, 1995.
4. Watkins PB: Drug metabolism by cytochromes P450 in the liver and small bowel. Gastroenterol Clin North Am 21:511-526, 1992.
5. Wrighton SA, Stevens JC: The human hepatic cytochrome P450 involved in drug metabolism. Crit Rev Toxicol 22:1-21, 1992.
6. Poulsen HE, Loft S: The impact of genetic polymorphisms in risk assessment of drugs. Arch Toxicol Suppl 16:211-222, 1994.
7. May DG: Genetic differences in drug disposition. J Clin Pharmacol 34:881-897, 1994.
8. Hansten P, Horn J. Drug interaction mechanisms and clinical characteristics, in Drug Interactions and Updates. Vancouver, Washington, Applied Therapeutics, 1993, pp 1-29.
9. Murray M: P450 enzymes. Inhibition mechanisms, genetic regulation, and effects of liver disease. Clin Pharmacokinet 23:132-146, 1992.
10. Halpert JR, Miller NE, Gorksy LD: On the mechanism of the inactivation of the major phenobarbital-inducible isoenzyme of rat liver cytochrome P-450 by chloramphenicol. J Biol Chem 260:8397-8403, 1985.
11. Halpert J: Covalent modification of lysine during the suicide inactivation of rat liver cytochrome P-450 by chloramphenicol. Biochem Pharmacol 30:875-881, 1981.
12. Gillum JG, Israel DS, Polk RE: Pharmacokinetic drug interactions with antimicrobial agents. Clin Pharmacokinet 25:450-482, 1993.
13. Davis RL, Quenzer RW, Kelly HW, et al: Effect of the addition of ciprofloxacin on theophylline pharmacokinetics in subjects inhibited by cimetidine. Pharmacotherapy 26:11-13, 1992.
14. Danan G, Descatoire V, Pessayre D: Self-induction by erythromycin of its own transformation into a metabolite forming an inactive complex with reduced cytochrome P-450. J Pharmacol Exp Ther 218:509-514, 1981.
15. Singh G, Renton KW, Stebbing N: Effect of Interferon on hepatic cytochrome P-450 drug metabolizing systems. Biochem Biophys Res Commun 106:1256-1260, 1982.
16. Sonnenfeld G, Harned CL, Thaniyavarn S, et al: Type II Interferon induction and passive transfer depress the murine cytochrome P-450 drug metabolism system. Antimicrob Agents Chemother 17:969-972, 1980.
17. Parkinson A, Lasker J, Kramer MJ, et al: Effects of three recombinant human leucocyte interferons on drug metabolism in mice. Drug Metab Dispos 10:579-585, 1982.
18. Sonne J, Dossino M, Loft S: Antipyrine clearance in pneumonia. Clin Pharmacol Ther 37:701-703, 1985.
19. Soons PA, Grib C, Breimer DD, et al: Effects of acute febrile infectious diseases in the oral pharmacokinetics and effects of nitrendapine enantiomers and bisoprolol. Clin Pharmacokinet 23:238-248, 1992.
20. Peterson TC, Renton KW: Depression of cytochrome P-450 dependent drug biotransformation in hepatocytes after the activation of the RES by dextran sulphate. J Pharmacol Exp Ther 229:299-304, 1984.
21. Wrighton SA, Vandenbranden M, Stevens JC, et al: In vitro methods for assessing human hepatic drug metabolism: Their use in drug development. Drug Metab Rev 25:453484, 1993.